Go Pro
NASDAQ:NXL

Nexalin Technology Q4 2025 Earnings Report

Nexalin Technology logo
$5.73 -1.82 (-24.11%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$5.48 -0.25 (-4.31%)
As of 10/2/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nexalin Technology EPS Results

Actual EPS
-$3.90
Consensus EPS
-$3.60
Beat/Miss
Missed by -$0.30
One Year Ago EPS
N/A

Nexalin Technology Revenue Results

Actual Revenue
$0.17 million
Expected Revenue
$0.08 million
Beat/Miss
Beat by +$91.90 thousand
YoY Revenue Growth
N/A

Nexalin Technology Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Wednesday, March 25, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

Nexalin Technology's Q3 2026 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedules

Earnings Documents

Nexalin Technology Earnings Headlines

Zacks Research Upgrades Nexalin Technology (NASDAQ:NXL) to Hold
What is Maxim Group's Forecast for NXL Q3 Earnings?
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
These Stocks Roar into October with Fresh Catalysts
See More Nexalin Technology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email.

About Nexalin Technology

Nexalin Technology (NASDAQ:NXL) is a medical technology company focused on developing noninvasive neurostimulation devices designed to support brain health. Its technology uses cranial electrotherapy stimulation to deliver low-level electrical signals through electrodes placed on the head, with the aim of influencing brain activity without surgery or implanted hardware.

The company’s product portfolio includes the Nexalin Gen-2 and Gen-3 devices, which are designed for use in clinical and other supervised settings. Nexalin has pursued applications for conditions and symptoms including insomnia, anxiety, depression and post-traumatic stress disorder, although the regulatory status and approved uses of its products may vary by jurisdiction.

Nexalin Technology has worked to commercialize its devices in the United States and international markets through regulatory initiatives, clinical research and distribution relationships. The company’s operations are centered on advancing its neurostimulation platform and expanding access to its products for healthcare providers and patients.

View Nexalin Technology Profile